Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

The Blood-brain Barrier00:49

The Blood-brain Barrier

46.8K
Overview
46.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Exploring anti-dengue activity with atomic-weighted vectors, class balancing and machine learning.

Molecular diversity·2026
Same author

Machine Learning-Based QSAR Models for Discovery of Inhibitors Targeting <i>Leishmania infantum</i> Amastigotes.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Protozoan Neglected Tropical Diseases (NTDs) Target Inhibition of Alkaloids from <i>Croton linearis</i> Jacq Leaves: A Molecular Docking and ADMET Approach.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

Half-Space Proximal Networks (HSPNs): A Proxy for Multi-Query Similarity Searching Models Predicting Tumor-Homing Peptides.

ACS omega·2025
Same author

Half-life prediction of central nervous system (CNS) small molecules in humans using gradient tree boosting.

Future medicinal chemistry·2025
Same author

Exploring antimalarial activity of drugs using weighted atomic vectors and artificial intelligence.

Journal of vector borne diseases·2025

相关实验视频

Updated: Jun 8, 2025

High-resolution Confocal Imaging of the Blood-brain Barrier: Imaging, 3D Reconstruction, and Quantification of Transcytosis
10:30

High-resolution Confocal Imaging of the Blood-brain Barrier: Imaging, 3D Reconstruction, and Quantification of Transcytosis

Published on: November 16, 2017

11.7K

使用原子加权矢量和机器学习探索血脑屏障的通道.

Yoan Martínez-López1, Paulina Phoobane2, Yanaima Jauriga3

  • 1Department of Computer Sciences, Faculty of Informatics, Camagüey University, 74650, Camagüey City, Cuba. ymlopez2022@gmail.com.

Journal of molecular modeling
|November 1, 2024
PubMed
概括

机器学习模型准确地预测了药物开发的血脑屏障 (BBB) 透情况. 这项研究利用分子特性和各种算法来预测化合物通过,帮助创造新的中枢神经系统 (CNS) 疗法.

关键词:
原子加权向量是原子加权的向量.血脑屏障 血脑屏障 血脑屏障 血脑屏障机器学习 机器学习

更多相关视频

Evaluation of Blood-Brain Barrier Breakdown in a Mouse Model of Mild Traumatic Brain Injury
05:19

Evaluation of Blood-Brain Barrier Breakdown in a Mouse Model of Mild Traumatic Brain Injury

Published on: October 18, 2024

563
Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish
13:34

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Published on: April 16, 2019

9.1K

相关实验视频

Last Updated: Jun 8, 2025

High-resolution Confocal Imaging of the Blood-brain Barrier: Imaging, 3D Reconstruction, and Quantification of Transcytosis
10:30

High-resolution Confocal Imaging of the Blood-brain Barrier: Imaging, 3D Reconstruction, and Quantification of Transcytosis

Published on: November 16, 2017

11.7K
Evaluation of Blood-Brain Barrier Breakdown in a Mouse Model of Mild Traumatic Brain Injury
05:19

Evaluation of Blood-Brain Barrier Breakdown in a Mouse Model of Mild Traumatic Brain Injury

Published on: October 18, 2024

563
Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish
13:34

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Published on: April 16, 2019

9.1K

科学领域:

  • 计算化学和化学信息学
  • 药理学和药物发现
  • 医学中的人工智能.

背景情况:

  • 准确预测血脑屏障 (BBB) 透率对于开发有效的中枢神经系统 (CNS) 药物至关重要.
  • 通过计算工具利用分子特性可以增强药物开发管道.
  • 预测BBB通道的现有方法需要优化,以提高准确性和效率.

研究的目的:

  • 调查从MD-LOVI软件中获得的分子性质的预测能力,用于估计化合物BBB透性.
  • 应用和评估各种机器学习 (ML) 模型,包括分类和回归技术,用于预测BBB通道和分子活性.
  • 确定最有效的ML模型,准确预测化合物穿过BBB的能力.

主要方法:

  • 利用MD-LOVI软件从化合物结构中生成分子描述符.
  • 采用了一系列机器学习算法:梯度提升机 (GBM),通用线性模型 (GLM),支持向量机 (SVM) 与多项式内核,随机森林 (RF),集合回归模型和基于实例的学习算法.
  • 在各种数据集上训练并验证了ML模型,报告性能指标,如准确性和R平方值.

主要成果:

  • 分类模型在预测BBB通道方面表现出很高的准确性,SVMPoly变体达到0.980的准确性.
  • 回归模型在预测分子活性方面表现强,ES-RLM-AG达到0.902.2的R平方值.
  • 像GBM-AWV,GLM-CN,SVMPoly变体,ES-RLM-AG和IB-MLP这样的特定模型被证明是非常有效的,证实了ML在这个领域的实用性.

结论:

  • 机器学习技术与分子性质分析相结合,为预测血脑屏障透性提供了一种强大的方法.
  • 该研究强调了特定分类和回归模型在预测中枢神经系统药物潜力的有效性.
  • 这些发现可以通过改善可行的候选药物的选择,显著加速神经疾病药物发现的早期阶段.